Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF82422 in Healthy Subjects and Patients with Parkinson's Disease
NCT03611569Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jul 2018
- Primary completion
- Jul 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing Lu AF82422 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Jul 2018; status: completed.
02
Drugs
amlenetug
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03611569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611569.